Study Years of follow-up Drugs BMI &Weight gain in kg Hypoglycaemia UKPDS [13,14] 6 Insulin vs. sulfonylurea 9.9 vs. 5.3 kg in the primary diet failure group 52% (insulin; 2.3% per year) Obese patients had a greater mean increase in body weight (10.4 vs. 3.7 kg) 16% (chlorpropamide)   21% (glyburide) DCCT [39,40] 6.5 Insulin (multiple daily insulin injections or continuous subcutaneous infusion) BMI: 1.5-1.8 kg/m2 3-fold higher in the intensive group Average weight gain of 4.75 kg in the intensive group   ADVANCE [41,42] 5 Gliclazide and other drugs 0.7 kg Severe hypoglycaemia more common in the intensive group ACCORD [43,44] 3.5 Sulfonylurea and other drugs >10 kg More frequent in the intensive therapy group ADOPT [45] 4 Rosiglitazone vs. Glyburide 4.8 vs. 1.6kg Fewer episodes vs. more episodes

Table 1: Weight Gain and Hypoglycaemia in Several Clinical Landmark Trials.